Merck & Co., Inc. (Merck), known as MSD outside the United States and Canada, has filed a post-effective amendment to a registration statement with the U.S. Securities and Exchange Commission (SEC) on May 14, 2024. The amendment pertains to the registration of debt securities by both Merck and its wholly-owned subsidiary, MSD Netherlands Capital B.V. (MSD Netherlands). The registration statement includes an indenture between Merck and U.S. Bank Trust National Association, serving as trustee, and a similar indenture between MSD Netherlands, Merck, and the trustee. These documents govern the issuance of the debt securities, which are unsecured and may be offered in various transactions at fixed or variable prices. The securities may be sold through underwriters, dealers, agents, or directly to investors. Merck's filing ensures compliance with federal securities laws and provides legal frameworks for potential future debt offerings by both Merck and MSD Netherlands.

Merck & Co., Inc. (Merck), known as MSD outside the United States and Canada, has filed a post-effective amendment to a registration statement with the U.S. Securities and Exchange Commission (SEC) on May 14, 2024. The amendment pertains to the registration of debt securities by both Merck and its wholly-owned subsidiary, MSD Netherlands Capital B.V. (MSD Netherlands). The registration statement includes an indenture between Merck and U.S. Bank Trust National Association, serving as trustee, and a similar indenture between MSD Netherlands, Merck, and the trustee. These documents govern the issuance of the debt securities, which are unsecured and may be offered in various transactions at fixed or variable prices. The securities may be sold through underwriters, dealers, agents, or directly to investors. Merck's filing ensures compliance with federal securities laws and provides legal frameworks for potential future debt offerings by both Merck and MSD Netherlands.